ARCH Venture Partners-backed Casdin Capital, a fundamental research investment firm, led a $75m Series B funding round in ONI, a biotechnology company, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners and Axon Ventures. “We are proud that our products have added unique insights to the biomedical research of our customers and that they have accumulated more than 110 scientific publications over the past several years, with that number rapidly rising. I would like to thank all of our investors for their solidarity with ONI’s mission to democratize this fundamental discovery tool. We look forward to learning from Keith and Shaun who have joined our board and welcome their guidance for the next phase of growth,” Bo Jing, ONI Founder & CEO.